南京健友生化制药股份有限公司 2025 年度拟转回存货跌价准备的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 南京健友生化制药股份有限公司（以下简称"公司"）根据《企业会计准则 第 1 号——存货》及公司会计政策等相关规定，对截至 2025 年 12 月 31 日存货 进行了初步减值测试，公司 2025 年度拟转回存货跌价准备 13,700.00 万元到 20,500.00 万元，预计导致归属于上市公司股东的净利润增加 11,600.00 万元到 17,400.00 万元。 本次拟转回存货跌价准备金额未经审计，最终会计处理及对公司 2025 年度 利润的影响以公司披露的 2025 年度报告为准。具体情况如下： | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 单位：万元、% 项目 2025 年末 2024 年末 2023 年末 金额 占比 金额 占比 金额 ...

Core Viewpoint - The company emphasizes the importance of market capitalization performance while acknowledging that daily market prices are influenced by multiple factors [1] Group 1: Company Focus - The company is committed to focusing on its mission, centering on patient needs through continuous innovation and high-quality operations to create value for society [1] - The company will adhere to principles of compliance, systematic approach, scientific methods, normalcy, and rationality in managing its market value [1] Group 2: Investor Relations - The company aims to provide solid operational performance and long-term value returns to its investors [1]

证券日报网讯1月23日，健友股份（603707）在互动平台回答投资者提问时表示，公司的本质是坚守使 命，以患者需求为核心，通过持续创新和稳健运营为社会创造价值。公司高度重视市值管理工作，始终 秉持合规、系统、科学、常态、理性的原则，致力于以扎实的经营业绩和长期价值回报每一位投资者。 公司会持续聚焦主业，通过不断推进研发管线、提升商业化能力来夯实内在价值。 ...

Core Viewpoint - The investigation into commercial bribery involving the drug Wanmai Ning has led to the initiation of a credit evaluation for Changshan Pharmaceutical, highlighting ongoing issues of corruption in the pharmaceutical industry and the impact on market practices [1][2][5]. Group 1: Investigation and Findings - The Shanghai Municipal Market Supervision Administration discovered that Shanghai Haiyilai Consulting Management Partnership engaged in commercial bribery to promote the sales of Wanmai Ning [1]. - Between January and December 2023, a total of approximately 35,000 yuan was paid in bribes to doctors, resulting in the issuance of around 18,300 prescriptions for Wanmai Ning [1][2]. - Shanghai Haiyilai earned approximately 868,700 yuan from its marketing and information services related to Wanmai Ning during the same period [1]. Group 2: Regulatory Actions and Implications - The Shanghai Municipal Market Supervision Administration imposed a fine of 300,000 yuan on Shanghai Haiyilai for its commercial bribery practices [2]. - The National Healthcare Security Administration has established a credit evaluation system for pricing and procurement, which may affect companies with negative records, including Changshan Pharmaceutical [2][3]. - Following the investigation, the Shanghai Pharmaceutical Affairs Office will initiate a credit evaluation for Hebei Changshan Biochemical Pharmaceutical Company, which is linked to Changshan Pharmaceutical [3]. Group 3: Company Performance and Market Impact - Changshan Pharmaceutical's stock price fell by 2.02% to 57.79 yuan per share, with a market capitalization of 53.1 billion yuan as of January 12 [5]. - The company has experienced significant revenue declines, with a reported 10% drop in revenue for the first three quarters of 2025 compared to the previous year, attributed to centralized procurement and falling prices of heparin raw materials [9]. - The company’s revenue from heparin products accounted for approximately 60% of its total income in 2023, indicating a heavy reliance on this segment [7].

Group 1 - The core viewpoint of the news is that Jianyou Co., Ltd. has shown significant trading activity and financial performance indicators, with a notable increase in shareholder accounts and a decrease in revenue and net profit for the year 2025 [1][2]. Group 2 - On January 6, Jianyou Co., Ltd. experienced a stock price increase of 0.97%, with a trading volume of 95.34 million yuan. The financing buy-in amount for the day was 15.84 million yuan, while the net financing buy-in reached 3.83 million yuan [1]. - As of January 6, the total balance of margin trading for Jianyou Co., Ltd. was 279 million yuan, with the financing balance accounting for 1.83% of the circulating market value, indicating a high level compared to the past year [1]. - The company reported a total revenue of 2.926 billion yuan for the period from January to September 2025, reflecting a year-on-year decrease of 5.25%, while the net profit attributable to shareholders decreased by 29.11% to 429 million yuan [2]. - Jianyou Co., Ltd. has distributed a total of 1.198 billion yuan in dividends since its A-share listing, with 509 million yuan distributed over the past three years [3]. - As of September 30, 2025, the number of shareholders for Jianyou Co., Ltd. reached 38,000, an increase of 30.18%, while the average circulating shares per person decreased by 23.18% to 42,484 shares [2][3].

关于"健友转债"转股结果暨股份变动的公告 | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 根据有关规定和《南京健友生化制药股份有限公司公开发行可转换公司债券 募集说明书》的约定，公司该次发行的健友转债自 2020 年 10 月 29 日起可转换 为公司普通股股票，初始转股价格为 54.97 元/股。因公司实施 2020 年限制性股 票激励计划，自 2020 年 7 月 10 日起，健友转债转股价格变为 54.96 元/股。因 公司实施 2019 年年度权益分派，自 2020 年 7 月 23 日起，健友转债转股价格变 为 42.05 元/股。因公司实施 2021 年限制性股票激励计划，自 2021 年 6 月 25 日起，健友转债转股价格变为 42.01 元/股。因公司实施 2020 年年度权益分派， 自 2021 年 7 月 15 日起，健友转债转股价格变为 32.20 元/股。因公司实施 2021 年限制性股票激励计划预留授予，自 202 ...

Group 1 - The core point of the article is that Jianyou Co., Ltd. (603707.SH) has announced a share buyback program, having repurchased a total of 1.379995 million shares as of December 31, 2025, which represents 0.09% of the company's total share capital [1] - The minimum transaction price for the repurchased shares was 9.56 yuan per share, while the maximum transaction price reached 11.66 yuan per share [1] - The total amount paid for the share buyback was 15.0085 million yuan, excluding transaction fees and stamp duty [1]

Core Viewpoint - Jianyou Co., Ltd. (603707.SH) has announced a share buyback program, indicating a commitment to returning value to shareholders through capital management strategies [1] Group 1: Share Buyback Details - As of December 31, 2025, the company has repurchased a total of 1.379995 million shares [1] - The repurchased shares account for 0.09% of the company's total share capital [1] - The lowest transaction price during the buyback was 9.56 yuan per share, while the highest was 11.66 yuan per share [1] - The total amount paid for the buyback reached 15.0085 million yuan, excluding transaction fees and stamp duty [1]

南京健友生化制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 关于股份回购进展的公告 | | | 债券代码：113579 债券简称：健友转债 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应于每个月的前 3 个交易日内 披露截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： | 回购方案首次披露日 | 2025/4/29，由董事长唐咏群先生提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 5 20 5 | 日~2026 | 年 | 月 | 19 | 日 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Jingze Biopharmaceutical (Hefei) Co., Ltd 景澤生物醫藥 (合 肥 )股份有限公司 (the "Company") (A joint stock company incorporated i ...